Erratum: Targeting the mTOR complex by everolimus in NRAS mutant neurroblastoma (PLoS ONE (2016) 11:1 (e0147682) DOI: 10.1371/journal.pone.0147682);Targeting the mTOR complex by everolimus in NRAS mutant neuroblastoma

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Kiessling, Michael K ^a   Curioni Fontecedro, Alessandra ^a   Samaras, Panagiotis ^a   Lang, Silvia ^a   Scharl, Michael ^a   Aguzzi, Adriano ^b   Oldrige, Derek A ^c   Maris, John M ^c   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 8055; BINIMETINIB; BUPARLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; SELUMETINIB; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; ONCOGENE N RAS; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EVEROLIMUS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; MUTATION; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84958582346     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170851     Document Type: Erratum

References (32)

1. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annual review of medicine. 2015; 66:49-63. doi: 10.1146/annurev-med-011514-023121 PMID: 25386934.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. doi: 10.1056/NEJMra0804577 PMID: 20558371; PubMed Central PMCID: PMC3306838.
3. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483 (7391):589-93. doi: 10.1038/nature10910 PMID: 22367537.
4. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. doi: 10.1038/ng.2529 PMID: 23334666; PubMed Central PMCID: PMC3682833.
5. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013; 45(1):12-7. doi: 10.1038/ng.2493 PMID: 23202128; PubMed Central PMCID: PMC3557959.
6. George RE, Sanda T, Hanna M, Frohling S, LutherW2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. doi: 10.1038/nature07397 PMID: 18923525; PubMed Central PMCID: PMC2587486.
7. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014; 5(18):8737-49. PMID: 25228590; PubMed Central PMCID: PMC4226718.
8. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-63. doi: 10.1016/j.cell.2012.06.024 PMID: 22817889; PubMed Central PMCID: PMC3600117.
9. Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. 2011; 117(8):2433-40. Epub 2011/01/07. blood-2010-09-305128 [pii] doi: 10.1182/blood-2010-09-305128 PMID: 21209378.
10. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Brit J Dermatol. 2011; 164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x WOS:000289150600014.
11. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. Epub 2011/10/14. doi: 10.1038/nrc3106 nrc3106 [pii]. PMID: 21993244.
12. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013; 19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173 PMID: 23515407; PubMed Central PMCID: PMC3643999.
13. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013; 110(10):4015-20. doi: 10.1073/pnas.1216013110 PMID: 23431193; PubMed Central PMCID: PMC3593920.
14. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013; 14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X PMID: 23414587.
15. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, et al. Mutant NRASQ61 shares signaling similarities across various cancer types - potential implications for future therapies. Oncotarget. 2014; 5(17):7936-44. PMID: 25277205; PubMed Central PMCID: PMC4202171.
16. COSMIC G. Catalogue of somatic mutations in cancer. Available: http://cancersangeracuk/cancergenome/projects/studies/. 2015.
17. Jin HO, Park IC, An S, Lee HC, Woo SH, Hong YJ, et al. Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. Journal of cellular physiology. 2006; 206(2):477-86. doi: 10.1002/jcp.20488 PMID: 16158421.
18. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947 PMID: 20068163.
19. Eleveld Thomas F. DA O, Virginie Bernard, Jan Koster, Leo Colmet, Daage SJD, Linda Schild, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics. 2015;in press.
20. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8 PMID: 23200175.
21. Adjei A, Zhao, Y. Inhibiting MEK for Cancer Therapy. ASCO Annual Meeting. 2015.
22. Finn R.S. J M.M., Tan B.R. Jr., Weekes C.C, Bendell J.C., Patnaik A., Khan G.N., et al. A Phase 1 Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer. ASCO GI, Jan 19-21, 2012, San Francisco, CA. 2012.
23. Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007; 6(1):138-46. doi: 10.1158/1535-7163.MCT-06-0436 PMID: 17237274.
24. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010; 70(1):288-98. doi: 10.1158/0008-5472.CAN-09-1751 PMID: 20028854.
25. Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007; 25(30):4806-12. doi: 10. 1200/JCO.2007.11.4017 PMID: 17947729.
26. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, et al. Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK. Clin Cancer Res. 2014. doi: 10.1158/1078-0432. CCR-14-1901 PMID: 25516890.
27. Hauschild Axel JJG, Lev V. Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600Emutated melanoma. 2012 ASCO Annual Meeting. 2012.
28. Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res. 2013; 19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476 PMID: 23444215; PubMed Central PMCID: PMC3932005.
29. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364(26):2507-16. Epub 2011/06/07. doi: 10.1056/NEJMoa1103782 PMID: 21639808.
30. Davies Barry R A L, Jennifer S. McKay PM, Samantha Steele RJ, Mark Cockerill SC, and Paul D. Smith. AZD6244 (ARRY-142886), a potent inhibitor of mitogenactivated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;2007( 6(8)).
31. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nature reviews Drug discovery. 2014; 13(11):828-51. doi: 10.1038/nrd4389 PMID: 25323927.
32. Heist R.S. LG, Geoffrey Shapiro, Naiyer A. Rizvi, Howard A. Burris, Johanna C. Bendell, Jose Baselga, et al. Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial. J Clin Oncol 31, 2013 (suppl; abstr 2530), 2013 ASCO Annual Meeting 2013.